Return to Publications
RWJBarnabas HealthRutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including clinical trials and novel therapeutics such as precision medicine and immunotherapy.

Return to Publications  |  Return to CINJ Home
The Cancer Institute of New Jersey's Cancer Connection, June 2013

Your link to the latest news on research, treatment, prevention and education from the state's only

National Cancer Institute-designated Comprehensive Cancer Center



New Look, Same World-Class Care



July 1 started a new chapter for the Cancer Institute of New Jersey as we integrated into Rutgers, The State University of New Jersey and became Rutgers Cancer Institute of New Jersey. The day was marked with a special ceremony welcoming the Institute and other components of UMDNJ into Rutgers and was celebrated with some 'Scarlet Spirit' by Cancer Institute faculty and staff. While we have a new visual identity, patients and families can be assured of the same excellent care and other services to which they are accustomed. Our location, contact information and website address also remain the same and donations may still be made to support the Cancer Institute of New Jersey through our Development Office.View the video

Kimmel Scholar Grant Awarded to Rutgers Cancer Institute Researcher



Darren Carpizo, MD, PhD, a surgical oncologist in the Liver Cancer and Bile Duct Cancer Care Program at Rutgers Cancer Institute of New Jersey, has been awarded a $200,000 grant from the Sidney Kimmel Foundation for Cancer Research to further explore the effects of a compound identified in his laboratory found to restore tumor suppressor function of a mutated gene in cancer cells. Dr. Carpizo is one of 15 investigators nationwide selected to receive the Kimmel Scholar Award out of more than 160 applicants.Learn more

Rutgers Cancer Institute of New Jersey is One of 50 Sites in Nation to Offer COMET-2 Clinical Trial



Rutgers Cancer Institute of New Jersey is one of 50 sites across the nation to offer a clinical trial known as COMET-2 that examines whether the drug cabozantinib is effective in reducing bone pain in patients with prostate cancer that is no longer responsive to hormone therapy and has spread (metastasized) to other parts of the body. Researchers will compare results in patients receiving cabozantinib to those in patients who are receiving a standard treatment of mitoxantrone and prednisone for pain.Learn more

Dr. David J. Foran Appointed Chief Informatics Officer



David J. Foran, PhD, has been appointed Chief Informatics Officer and Executive Director of Biomedical Informatics and Computational Imaging at Rutgers Cancer Institute of New Jersey. Dr. Foran's laboratory engages in the development of high-throughput, imaging, data-mining and computational tools for classifying malignancies and stratifying biomarker expression signatures from disease onset throughout progression. In his new role, Foran will oversee the Institute's Information, Science and Technology Department and Bioinformatics Program.Learn more

A Clinical Research Experience for Students Underrepresented in the Biomedical Field


student research

Building off the success of its Continuing Umbrella for Research Education (CURE) Program that encourages underrepresented minority undergraduate and high school students to pursue careers in healthcare, Rutgers Cancer Institute of New Jersey is offering a related program. The Clinical Research Experience for High School Students (CREHST) program, funded by a generous grant from the Rita Allen Foundation, will expose students to the clinical aspect of cancer research and related careers.Learn more

            Rutgers Cancer Institute of New Jersey                                          NCI logo 

Office of Communications         ·        ·        732-235-9871

                        Like us on Facebook                     Join the CINJ Mailing List